SecBot SecBot
8-K ·Filed Jun 9, 2026

NUVL

Nuvalent, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago SEC0001193125-26-262950
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The deal carries a 40% premium and has strong insider support (28% already committed). Key risks are regulatory, FDA decisions on zidesamtinib (Sept 18) and neladalkib (Nov 27), and HSR clearance. The stock should trade near the offer price minus a small spread for timing and regulatory risk. Monitor for any competing bids given the termination fee structure.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$123.25
T+0 close · Jun 9, 2026 · via day close
Latest settled
+0.42%
T+20 · $123.77
Vs SPY
−1.02%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 9 $123.25entry
  2. T+1 · 5mo ago +0.08%α +1.66% · $123.35
  3. T+5 · 5mo ago +0.08%α −2.33% · $123.35
  4. T+20 · 4mo ago +0.42%α −1.02% · $123.77
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion. The transaction includes two late-stage ROS1 and ALK inhibitors (zidesamtinib and neladalkib) under FDA review with 2026 target action dates, plus a phase I HER2 inhibitor. Stockholders representing ~28% of Class A shares have signed tender and support agreements to tender their shares. The deal is expected to close in Q3 2026, subject to regulatory approval and a majority-of-shares tender condition.

Key Financial Metrics

Deal Value
$10.6B
Premium
40%
Deal Type
merger

Key Facts

  • GSK to acquire Nuvalent for $124.00 per share in cash, aggregate equity value of $10.6 billion
  • Purchase price represents a 40% premium to last closing price and a 26% premium to 30-day VWAP
  • Two late-stage assets (zidesamtinib for ROS1+ NSCLC, neladalkib for ALK+ NSCLC) under FDA review with PDUFA dates of Sept 18, 2026 and Nov 27, 2026
  • Third asset NVL-330 (HER2 inhibitor) in phase I for HER2-altered NSCLC
  • Supporting stockholders (Deerfield affiliates, directors, officers) owning ~28% of Class A shares have agreed to tender
  • Termination fee of $350,475,000 payable by Nuvalent under certain circumstances
  • Transaction expected to close in Q3 2026; GSK expects low single-digit percentage dilution to core EPS in FY 2026-2028, accretion to core EPS in 2029
  • GSK to fund primarily from new and existing debt plus cash; no financing condition

Financial Impact

$10.6 billion aggregate equity value; $124.00 per share cash consideration; net of cash acquired GSK's investment estimated at $9.4 billion

share pricemarket capitalizationcash consideration

Risk Factors

  • FDA non-approval or delayed approval of zidesamtinib or neladalkib could delay or jeopardize the deal
  • HSR antitrust review could extend timeline or impose conditions
  • Shareholder litigation could create delays or additional costs
  • GSK's ability to fund the transaction is not subject to a financing condition, but debt markets could shift

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-262950
Document: d137459dex101.htm0001193125-26-262950
Document: d137459dex991.htm0001193125-26-262950
Document: d137459d8k.htm0001193125-26-262950
Document: 0001193125-26-262950-index-headers.html0001193125-26-262950
Document: 0001193125-26-262950.txt0001193125-26-262950

Track record

18 reports on NUVL

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 3 of 7 went positive at some point.

Filters
  1. Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
  2. Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
  3. Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
  4. Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
  5. Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
  6. Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
  7. Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
  8. Jun 9, 202622w ago 8-K Bullish 8/10 Viewing Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
  9. May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
  10. Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026